相关实验视频
Updated: Jul 1, 2025

08:36
In Vitro Assay to Study Tumor-macrophage Interaction
Published on: August 1, 2019
7.5K
胃癌中的CLEC4E上调:与瘤相关的巨细胞相关的潜在治疗标
Qin Jiang1, Dan Xiao1, Ao Wang1
1Department of Gastroenterology, The Sixth Hospital of Wuhan, Affiliated Hospital of Jianghan University, Wuhan, 430000, China.
Heliyon
|March 11, 2024
概括
这项研究表明,C型莱克域家族4成员E (CLEC4E) 在胃癌 (GC) 中被上调,并促进瘤的进展. 向CLEC4E与树脂醇提供了一个潜在的治疗策略为GC.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- C型莱克域家族4成员E (CLEC4E) 与肺癌进展有关.
- 与瘤相关的巨细胞 (TAMs) 在瘤发生过程中至关重要.
- 在胃癌 (GC) 中,CLEC4E在TAM中的作用仍然未被描述.
研究的目的:
- 研究CLEC4E在GC中的表达和预后意义.
- 在胃癌发生过程中探索CLEC4E在TAM中的功能.
- 确定潜在的治疗策略,针对GC中的CLEC4E.
主要方法:
- 使用公共数据库 (TIMER,UALCAN,UCSC Xena,KM绘图器) 进行表达和生存分析.
- 进行生物信息学分析 (GO,KEGG,GSEA) 和单细胞RNA-seq (scRNA-seq).
- 采用了体外共同培养模型和分子对接来评估CLEC4E的作用和药物向.
主要成果:
- 在GC中,CLEC4E被显著上调,与预后不佳相关.
- CLEC4E表达与免疫反应有关,与免疫细胞透有正相关,特别是在TAMs中.
- 实验室研究证实,CLEC4E在TAM中驱动GC的进展;通过si-CLEC4E或耻辱醇抑制癌细胞迁移和入侵来准CLEC4E.
结论:
- CLEC4E作为GC的潜在预后生物标志物.
- CLEC4E代表了胃癌的新治疗标.
- 斯蒂格马斯托尔显示出作为治疗剂的潜力,用于向GC中的CLEC4E.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K

